NCT01984801View on ClinicalTrials.gov

Study to Investigate the Irritation Potential of GSK1940029 Gel

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 14, 2013

Primary Completion Date

April 10, 2015

Study Completion Date

April 10, 2015

Conditions
Acne Vulgaris
Interventions
DRUG

0.3% GSK1940029 gel

200 mg of the gel will be applied to individual patches by using a spatula

DRUG

1% GSK1940029 gel

200 mg of the gel will be applied to individual patches by using a spatula

DRUG

0.3%/1% vehicle gel only

200 mg of the gel will be applied to individual patches by using a spatula

OTHER

Sterile distilled water

200 µL of the solution will be applied to individual patches by using a pipette or syringe

OTHER

0.5% SLS in sterile distilled water

200 µL of the solution will be applied to individual patches by using a pipette or syringe

OTHER

0.1% SLS in sterile distilled water

200 µL of the solution will be applied to individual patches by using a pipette or syringe

OTHER

Patch only

Only patch will be applied

Trial Locations (1)

5000

GSK Investigational Site, Adelaide

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01984801 - Study to Investigate the Irritation Potential of GSK1940029 Gel | Biotech Hunter | Biotech Hunter